Search
Research
Method of bacterial killing differentially affects the human innate immune response to Staphylococcus epidermidisIn vitro investigations of human innate immune responses to extracellular bacteria commonly utilise killed preparations in preference to live organisms
Research
The interaction between respiratory viruses and pathogenic bacteriaData on asymptomatic identification rates of respiratory viruses are limited, particularly in Indigenous populations, who suffer a high burden of OM.
Research
The changing epidemiology of invasive pneumococcal diseaseWe investigated trends in invasive pneumococcal disease (IPD) in Western Australia (WA).
Research
Vaccinating young adults against HPV: the importance of understanding health decision-making and behaviourVaccination of young teenage females against human papillomavirus (HPV) with a newly licenced quadrivalent vaccine designed to prevent cervical cancer and...
Research
Heritable and environmental determinants of hospitalisation for common childhood illnessesWe will leverage the unique Western Australian data linkage resources to undertake the definitive twin and sibling study of infection-related hospitalisation
Research
GAMA projectThis study investigated host gene expression in response to new HIV infection.
Research
MeaslesMeasles is a highly contagious infectious disease that can cause severe, long-term complications in children.
Research
Haemophilus influenzae remains the predominant otitis media pathogen in Australian children undergoing ventilation tube insertion in the PCV13 eraUnderstanding patterns of bacterial carriage and otitis media (OM) microbiology is crucial for assessing vaccine impact and informing policy. The microbiology of OM can vary with geography, time, and interventions like pneumococcal conjugate vaccines (PCVs). We evaluated the microbiology of nasopharyngeal and middle ear effusions in children living in Western Australia, 11 years following the introduction of PCV13.
Research
Widening the lens for pandemic preparedness: children must be seen and heardThe Australian and New Zealand Paediatric Infectious Diseases (ANZPID) Group of the Australasian Society for Infectious Diseases (ASID) calls for urgent consideration of the needs and voices of children in response to the COVID-19 pandemic, and in planning for future pandemics.
Research
Estimating the impact of Western Australia's first respiratory syncytial virus immunisation program for all infants: A mathematical modelling studyThe Australian Therapeutic Goods Administration approved the use of nirsevimab, a long-acting monoclonal antibody for the prevention of Respiratory Syncytial Virus (RSV), in November 2023. Western Australia (WA) implemented a combination of nirsevimab administration strategies designed to protect all infants starting in April 2024, before the epidemic season. We developed a dynamic transmission model to predict the impact of WA's RSV immunisation program on infant hospitalisations.